Marking the Way: The Future of Vasopressors

<p>Mikaela Hofer, Pharm.D., BSPS, BCCCP (<a href='https://twitter.com/mikaelamhofer'>@mikaelamhofer</a>) identifies limitations of current vasopressor agents for the treatment of septic shock, reviews novel vasopressor therapies with a current or potential role in the management of septic shock and describes advancements in the development of biomarkers and pharmacogenomics for the monitoring and individualization of vasopressor treatment. </p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>